(Q34090988)

30 July 2017

1 reference

title

Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia (English)

1 reference

30 July 2017

0 references

Denny WA

1

1 reference

30 July 2017

Wilson WR

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

2889-2901

1 reference

Hypoxic regions exist in human prostate carcinoma.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Hypoxia-Specific Cytotoxins in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Microdialysis sampling with on-line microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Therapeutic advantage of hypoxic cells in tumors: a theoretical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Bioreductive drugs and the selective induction of tumour hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2889

10.1517/13543784.9.12.2889

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference